Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2018
NICE minded to reject Keytruda for classical Hodgkin lymphoma
12 March 2018 - Cost regulators for NHS therapies in England and Wales say they are minded not to recommend ...
Posted by Michael Wonder on 01 Mar 2018
NICE nod for Merck/Pfizer's Bavencio
1 March 2018 - Patients in England, Wales and Northern Ireland with a rare and aggressive type of skin cancer ...
Posted by Michael Wonder on 22 Feb 2018
NICE sticks with ‘no’ for earlier use of Halaven
22 February 2018 - Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s ...
Posted by Michael Wonder on 15 Feb 2018
Alternative treatments for people with thyroid cancer to be offered routinely on the NHS, says NICE
15 February 2018 - The new guidance recommends three drugs, treating two types of thyroid cancer to be made routinely available ...
Posted by Michael Wonder on 12 Feb 2018
NICE backs EUSA’s kidney cancer drug Fotivda
12 February 2018 - NICE) has published draft guidelines backing use of EUSA Pharma’s Fotivda as a first-line treatment option ...
Posted by Michael Wonder on 12 Feb 2018
NICE asks Tesaro to submit CDF application for Zejula
9 February 2018 - Tesaro has been asked by NICE to submit a proposal for Zejula use on the National ...
Posted by Michael Wonder on 12 Feb 2018
Liver cancer patients barred from NHS access to Bayer’s Stivarga
9 February 2018 - It is now looking very unlikely that patients with liver cancer will get access to Bayer’s ...
Posted by Michael Wonder on 11 Feb 2018
Roche wins UK watchdog's nod for lymphoma drug after initial snub
10 February 2018 - Britain’s healthcare watchdog recommended Roche’s medicine Gazyvaro for previously untreated advanced follicular lymphoma patients after initially rejecting ...
Posted by Michael Wonder on 08 Feb 2018
Once a day pill for ovarian cancer could be made available on the CDF
8 February 2018 - NICE has invited Tesaro to submit a proposal for including niraparib (Zejula) in the Cancer Drugs Fund ...
Posted by Michael Wonder on 07 Feb 2018
Patients to benefit from myeloma treatment through CDF deal
7 February 2018 - Up to 1,600 patients with multiple myeloma could benefit from a new oral pill after NICE recommends ...
Posted by Michael Wonder on 01 Feb 2018
NHS England takes charge on market access
1 February 2018 - Today sees patients gain full NHS access to breast cancer drug Perjeta, a full six years ...
Posted by Michael Wonder on 01 Feb 2018
Final NHS nod for Janssen’s Imbruvica
1 February 2018 - Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell ...
Posted by Michael Wonder on 01 Feb 2018
NICE, the NHS, and cancer drugs
31 January 2018 - Drug costs are an issue in virtually every country and particularly in the United States. In ...
Posted by Michael Wonder on 31 Jan 2018
`Life-changing´ breast cancer drug can be routinely used in NHS, says NICE
31 January 2018 - A “life-changing” drug for breast cancer patients has been given the final go-ahead for routine NHS ...
Posted by Michael Wonder on 28 Jan 2018
Is “end of life” a special case? Connecting Q with survey methods to measure societal support for views on the value of life-extending treatments
19 January 2018 - Preference elicitation studies reporting societal views on the relative value of end-of-life treatments have produced equivocal results. ...